A proprietary formulation of bupivacaine with meloxicam, developed by Heron Therapeutics, relieves acute pain for 72 hours after surgery.
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Naxitamab by Y-mAbs Therapeutics offers gorgeous treatment efficacy with unsafe adverse events.
Selumetinib by AstraZeneca powerfully suppresses tumor growth in neurofibromatosis type 1.
In the task of getting rid of headaches lasmiditan by Eli Lilly is as effective as the popular triptans, but safer.